摘要
目的了解临床分离的粪肠球菌分子分型特征及其与泰利霉素药物敏感性之间的关系。方法收集深圳市南山医院2010-2016年不同临床标本分离的粪肠球菌320株,采用多位点序列分型技术进行分型,用微量肉汤稀释法测定菌株对泰利霉素的最低抑菌浓度,采用PCR检测耐药基因ermB的分布。结果 320株粪肠球菌分为48个ST型和56株新的ST分型,以ST16、ST179型为主。ST16型85株(26.6%),其中72株(84.7%)ermB阳性,29株(34.1%)对泰利霉素敏感,10株(11.8%)中介,46株(54.1%)耐药;ST179型80株(25.0%),其中71株(88.8%)ermB阳性,15株(18.8%)对泰利霉素敏感,4株(5.0%)中介,61株(76.3%)耐药。结论该院粪肠球菌以ST16、ST179为优势菌株,该两型菌群高比例携带ermB基因,对泰利霉素耐药率较高。
Objective To reveal characteristics of molecular typing of clinically isolated Enterococcus faecalis(E.faecalis)and its relationship with susceptibility to telithromycin.Methods 320 strains of E.faecalisisolated from different clinical specimens in Nanshan Hospital of Shenzhen City from2010 to 2016 were collected,genotyping of E.faecalis was performed by multilocus sequence typing(MLST),minimum inhibitory concentration of telithromycin to strains was determined by broth microdilution method,and distribution of drug-resistant gene ermB was detected by polymerase chain reaction(PCR).Results 320 strains of E.faecalis were divided into 48 ST types and 56 new ST types,mainly ST16 and ST179.85 strains(26.6%)were ST16,72(84.7%)of which were positive for ermB,29(34.1%)were susceptible to telithromycin,10(11.8%)were intermediate,46(54.1%)were resistant to telithromycin;80 strains(25.0%)were ST179,71(88.8%)of which were positive for ermB,15(18.8%)were susceptible to telithromycin,4(5.0%)were intermediate,and 61(76.3%)were resistant to telithromycin.Conclusion ST16 and ST179 are dominant strains of E.faecalis in this hospital,they carry ermB gene in a high proportion and have high resistance rate to telithromycin.
作者
黄震
胥志超
张波
王红燕
陈重
白冰
潘伟光
李桂秋
徐广健
余治健
邓启文
李多云
HUANG Zhen;XU Zhi-chao;ZHANG Bo;WANG Hong-yan;CHEN Zhong;BAI Bing;PAN Wei-guang;LI Gui-qiu;XU Guang-jian;YU Zhi-jian;DENG Qi-wen;LI Duo-yun(Department of Infectious Disease of Nanshan District People’s Hospital, Shenzhen Key Laboratory for Endogenous Infection, Shenzhen University School of Medicine , Shenzhen 518052, China;Department of Lung Disease, Baoan District People’s Hospital, Shenzhen 518101, China;Healthcare -associated Infection Quality Control Center of Shenzhen, Shenzhen 518052, China)
出处
《中国感染控制杂志》
CAS
CSCD
北大核心
2019年第8期708-712,共5页
Chinese Journal of Infection Control
基金
深圳市科技计划项目(JCYJ20170412143551332、JCYJ20170307153714512、JCYJ20170307153425389、JCYJ20170307153919735)
广东省卫生厅课题(A2018163)
